

Ready to Rethink Biosimilar CLD? Here's Your Front Row Seat

18 April 2025 | News

As the biosimilars market gains momentum across Asia-Pacific, precision in early-stage development is critical to success. Join us for an exclusive BioSpectrum Asia webinar hosted in collaboration with industry leaders to explore how animal component-free, chemically-defined media and optimized cell line development (CLD) can future-proof your biosimilar pipeline.



Register now: https://www.biospectrumasia.com/webinar-biosimilarcytiva

What to Expect:

- Proven strategies for developing serum-free, single-cell cloning workflows
- Insights into fine-tuning media to empower production goals
- Regulatory intelligence for smoother development and submission
- Practical perspectives from seasoned experts in biosimilar CLD

Speakers Include:

- Melanie Sorensen, Regulatory Affairs Strategist Leader
- Nan Lin, PhD, Director, New Technologies & Cell Culture Service Applications
- Sheffali Dash, Principal Scientist, CLD & Cell Culture Services

Why Attend:

Whether you're navigating regulatory bottlenecks or striving to enhance manufacturing yield, this session provides you with actionable insights to optimize your biosimilar development from the ground up.

Register now: https://www.biospectrumasia.com/webinar-biosimilarcytiva